Standardised FDG uptake: A prognostic factor for inoperable non-small cell lung cancer

被引:154
作者
Borst, GR
Belderbos, JSA
Boellaard, R
Comans, EFI
De Jaeger, K
Lammertsma, AA
Lebesque, JV
机构
[1] Antoni Van Leeuwenhoek Hosp, Dept Radiat Oncol, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Clin PET Ctr, Amsterdam, Netherlands
关键词
prognosis; radiotherapy; NSCLC; FDG PET; SUV;
D O I
10.1016/j.ejca.2005.03.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to investigate the relationship between standardised uptake value (SUV) obtained from [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and treatment response/survival of inoperable non-small cell lung cancer (NSCLC) patients treated with high dose radiotherapy. Fifty-one patients were included recording stage, performance, weight loss, tumour volume, histology, lymph node involvement, SUV, and delivered radiation dose. The maximum SUV (SUVmax) within the primary tumour was a sensitive and specific factor for predicting treatment response. Apart from SUVmax, stage and performance were also independent predictive factors for treatment response. In a multivariate disease-specific survival (DSS) analysis, SUVmax (P = 0.01), performance status (P = 0.008) and stage (P = 0.04) were prognostic factors. For overall survival (OS), SUVmax (P = 0.001) and performance (P = 0.06) were important prognostic factors. SUVmax was an important prognostic factor for survival of inoperable NSCLC patients and a predictive factor for treatment response. Although the number of patients was small, the treatment was not homogeneous and the use of FDG SUV may have had constraints, we still conclude that the FDG SUV is potentially a good indicator for selecting patients for different treatment strategies. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1533 / 1541
页数:9
相关论文
共 31 条
  • [1] Ahuja V, 1998, CANCER, V83, P918, DOI 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.3.CO
  • [2] 2-#
  • [3] First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy
    Belderbos, JSA
    De Jaeger, K
    Heemsbergen, WD
    Seppenwoolde, Y
    Baas, P
    Boersma, LJ
    Lebesque, JV
    [J]. RADIOTHERAPY AND ONCOLOGY, 2003, 66 (02) : 113 - 120
  • [4] Boellaard R, 2004, J NUCL MED, V45, P1519
  • [5] Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer
    Bradley, J
    Thorstad, WL
    Mutic, S
    Miller, TR
    Dehdashti, F
    Siegel, BA
    Bosch, W
    Bertrand, RJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01): : 78 - 86
  • [6] Prognostic factors in non-small cell lung cancer - A decade of progress
    Brundage, MD
    Davies, D
    Mackillop, WJ
    [J]. CHEST, 2002, 122 (03) : 1037 - 1057
  • [7] Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection
    Downey, RJ
    Akhurst, T
    Gonen, M
    Vincent, A
    Bains, MS
    Larson, S
    Rusch, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3255 - 3260
  • [8] LUNG-TUMOR GROWTH CORRELATES WITH GLUCOSE-METABOLISM MEASURED BY FLUORIDE-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY
    DUHAYLONGSOD, FG
    LOWE, VJ
    PATZ, EF
    VAUGHN, AL
    COLEMAN, E
    WOLFE, WG
    [J]. ANNALS OF THORACIC SURGERY, 1995, 60 (05) : 1348 - 1352
  • [9] Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - Meta-analytic comparison of PET and CT
    Dwamena, BA
    Sonnad, SS
    Angobaldo, JO
    Wahl, RL
    [J]. RADIOLOGY, 1999, 213 (02) : 530 - 536
  • [10] Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review
    Fischer, BMB
    Mortensen, J
    Hojgaard, L
    [J]. LANCET ONCOLOGY, 2001, 2 (11) : 659 - 666